respiratori
failur
due
acut
respiratori
distress
syndrom
ard
one
major
caus
mortal
associ
diseas
around
patient
requir
intens
care
unit
icu
care
ventilatori
support
icu
mortal
rate
report
sever
diseas
higher
older
patient
death
observ
year
age
younger
infect
seem
less
suscept
exhibit
mediummild
symptom
lower
respiratori
tract
affect
respiratori
distress
progress
quickli
time
death
report
rapidli
day
initi
symptom
despit
avail
ventil
palli
support
propos
sever
mortal
rate
suscept
popul
infect
relat
cytokin
storm
exagger
product
proinflammatori
substanc
releas
pulmonari
microenviron
short
period
time
novel
lifesav
strategi
desper
need
mitig
high
mortal
associ
late
stage
viral
infect
acut
respiratori
distress
hypothes
morbid
sever
diseas
underli
physiolog
event
link
mortal
explain
involv
express
neuron
system
afferenteffer
neuron
posit
pathway
respons
pain
transmiss
inflamm
immunomodul
throughout
entir
pulmonari
system
suggest
therapeut
approach
target
express
neuron
lung
modul
inflammatori
immun
signal
activ
lead
reduc
mortal
better
overal
outcom
propos
explor
use
resiniferatoxin
rtx
ultrapot
agonist
current
j
u
r
n
l
p
r
e
p
r
f
clinic
trial
cancer
osteoarthr
pain
possibl
ablat
agent
posit
pulmonari
pathway
patient
advanc
diseas
clinic
sign
consist
observ
viral
pneumonia
abnorm
chest
ct
scan
show
bilater
multipl
peripher
groundglass
opac
observ
hospit
case
pulmonari
chang
like
respons
system
local
immun
respons
lead
hyperinflammatori
state
mortal
rate
patient
suspect
relat
viral
driven
cytokin
storm
similar
seen
infect
cytokin
storm
result
sever
immun
reaction
lung
measur
high
level
inflammatori
marker
creactiv
protein
serum
ferritin
cytokin
level
gscf
plasma
icu
patient
higher
plasma
level
gscf
compar
nonicu
patient
suggest
presenc
high
circul
cytokin
level
associ
sever
diseas
current
urgent
need
effect
treatment
lifethreaten
diseas
target
hyperinflamm
lung
high
compel
interest
although
use
corticosteroid
might
benefici
reduc
inflammationinduc
lung
injuri
evid
sar
mer
patient
show
littl
improv
mortal
rate
delay
viral
load
clearanc
antiinflammatori
therapi
use
monoclon
antibodi
current
undergo
phase
iii
trial
patient
could
lead
promis
result
effect
therapi
depend
control
singl
factor
multidimension
process
possibl
approach
limit
efficaci
j
u
r
n
l
p
r
e
p
r
f
might
necessari
interfer
inflammatori
cascad
higher
level
ie
elimin
proinflammatori
effer
pathway
appropri
control
multimod
aspect
inflammatori
process
respiratori
tract
higher
lower
dens
popul
sensori
affer
origin
neuron
nodos
vagal
ganglia
vg
dorsal
root
ganglia
find
suggest
ablat
posit
pathway
could
benefici
prevent
treatment
ventilatorassoci
lung
injuri
hyperox
acut
lung
injuri
hali
result
high
inspir
fraction
oxygen
prolong
time
addit
mechan
ventil
increas
lung
inflamm
microvascular
permeabl
lung
epitheli
apoptot
cell
death
initi
factor
involv
type
lung
injuri
gener
reactiv
oxygen
speci
ro
activ
signal
cascad
lead
overproduct
substanc
p
activ
subsequ
increas
cytokin
level
role
posit
cell
hali
describ
suggest
associ
express
innerv
combin
viral
driven
hyperinflamm
case
might
root
caus
lethal
aspect
diseas
particularli
elderli
propos
interrupt
signal
might
decreas
sever
acut
respiratori
distress
syndrom
present
patient
antagonist
pretreat
prevent
increas
respiratori
system
resist
tissu
damp
decreas
area
collaps
lung
parenchyma
block
silenc
posit
nerv
fiber
could
eventu
also
interest
limit
progress
diseas
mild
stage
acut
respiratori
distress
affer
innerv
pulmonari
system
mainli
conduct
vagal
nerv
branch
express
cfiber
small
diamet
unmyelin
fiber
vagal
nerv
respons
sever
process
airway
lung
import
note
affer
fiber
innerv
pulmonari
structur
also
carri
sympathet
fiber
cell
bodi
locat
dorsal
root
ganglia
thorac
segment
activ
thorac
segment
relat
sever
pneumon
consider
pulmonari
neuroanatomi
potenti
rout
administr
abl
agent
would
includ
thorac
epidur
inject
periganglion
nerv
block
intraganglion
inject
target
lung
denerv
practic
approach
exampl
would
access
vagal
nerv
local
abl
agent
might
neck
go
low
away
carotid
bulb
nerv
locat
would
confirm
use
ultrasound
guidanc
propos
pursu
epidur
periganglion
applic
rtx
patient
advanc
diseas
support
current
palli
ventil
therapi
hope
ablat
affer
nerv
thorac
drg
level
increas
surviv
patient
progress
toward
critic
condit
product
avail
activ
ind
treat
patient
central
rout
without
signific
advers
event
believ
enough
safeti
data
justifi
pursu
ind
indic
also
propos
explor
altern
peripher
approach
nerv
block
collabor
expert
appropri
regulatori
author
oversight
